#march hemoglobinuria

[biology-geology-beaches-india]

The Science Journals of Satyendra Sunkavally, page 28.

[mcatmemoranda]

I've never heard of "march hemoglobinuria." It's hemoglobinuria due to excessive running.

March hemoglobinuria, occurs when hemoglobin is seen in the urine after repetitive impacts on the body, particularly affecting the feet. The word "march" is in reference to the condition arising in soldiers who have been marching for long periods; the condition was first documented in 1881.

Mechanical hemolytic anemia is a form of hemolytic anemia due to mechanically induced damage to red blood cells. Red blood cells, while flexible, may in some circumstances succumb to physical shear and compression.[1] This may result in hemoglobinuria. The damage is induced through repetitive mechanical motions such as prolonged marching (march hemoglobinuria) and marathon running. Mechanical damage can also be induced through the chronic condition microangiopathic hemolytic anemia or due to prosthetic heart valves.

Intact RBCs on urine microscopy excludes myoglobinuria and hemoglobinuria.

[kunalcmi]

MYASTHENIA GRAVIS TREATMENT MARKET ANALYSIS - (2019-2027)

Myasthenia gravis (MG) is a type of chronic autoimmune neuromuscular disease which causes weakness in skeletal muscles in the arms and legs. Double vision, facial paralysis, difficulty in walking, dropping of eyelids, are symptoms of myasthenia gravis. This disease is diagnosed by tests such as repetitive nerve stimulation test, blood test for antibodies, edrophonium test, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). Corticosteroids drugs (azathioprine, and cyclosporine) and Acetylcholine esterase inhibitors (Edrophonium, and Pyridostigmine) are used for the treatment of MG.

 Myasthenia Gravis Treatment Market Drivers

Consistent research and development activities are expected to propel growth of the myasthenia gravis treatment market. For instance, in October 2017, Alexion Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for Soliris which contains eculizumab as an active component. This drug is used for treatment of antibody positive generalized myasthenia gravis, and it is also used in treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS).

Furthermore, increasing number of clinical trials for treatment of myasthenia gravis are expected to drive the myasthenia gravis treatment market growth. For instance, in December 2017, Novartis AG initiated phase II clinical trial of CFZ533 for treatment of severe myasthenia gravis. The main function of CFZ533 is the modification of immune response by deactivation of white blood cells. Hence, it is expected to help with improvement and management of severe myasthenia gravis.

Moreover, Argenx BVBA is conducting a clinical phase III study of ARGX-113 for treatment of generalized myasthenia gravis. ARGX-113, also named Efgartigimod, is administered intravenously. The study started in March 2019 and is expected to complete in June 2021.

  Myasthenia Gravis Treatment Market Restraints

Side effects of the drugs used for treating myasthenia gravis are expected to hamper growth of the myasthenia gravis treatment market. For instance, according to BioNews Services, LLC report, in April 2019, high dose combination of cholinesterase inhibitors (ChEIs) and calcineurine inhibitors (CNIs) such as Mestinon and Prograf are responsible for severe muscle cramps in myasthenia gravis patients. Hence, this factor is expected to hinder growth of the myasthenia gravis treatment market.

 Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/2625

Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2625

 Myasthenia Gravis Treatment Market- Regional Analysis

On the basis of region, the global myasthenia gravis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the myasthenia gravis treatment market over the forecast period. This is owing to increasing incidence and prevalence of myasthenia gravis in the U.S. For instance, in October 2018, according to the National Center for Biotechnology Information (NCBI), incidence of myasthenia gravis was around 5 to 30 cases per million person years and prevalence is around 10 to 20 cases per 100,000 population in U.S.

Furthermore, Asia Pacific is projected to witness significant growth in the global myasthenia gravis treatment market, owing to increasing research and development activities for treatment of myasthenia gravis. For instance, Sun Yat-Sen University in China is conducting phase III clinical trial of Azathioprine and Leflunomide for treatment of myasthenia gravis. The study started in September 2012, and is expected to complete in January 2020.

Key players operating in the myasthenia gravis treatment market are Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceutical International, Inc. Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Shire plc, and Avadel Pharmaceutical, PLC.

 Myasthenia Gravis Treatment Market –Taxonomy

 By Medications

Cholinesterase Inhibitors

Corticosteroids

Immunosuppressants

Plasmapheresis

Intravenous immunoglobulin (IVIg)

Monoclonal Antibody

 By Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

 Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2625

 About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/ongoing-insight/myasthenia-gravis-treatment-market-2625

[norwegiancinnamonrolls]

Rules: answer the questions in a new post and tag 20 blogs you would like to know better.

I got tagged by lovely @sjf-forever thank youu ♥

(I’ve already done this one some time ago so I just changed some of my former answers, currently a little bit busy, sorry!)

Nicknames: hmn i do not really have one, because my name is already pretty short, but some of my friends from high school still call me leni sometimes. Gender: female Star sign: leo Height: something about 173cm Time right now: 11:50am Last thing i googled: paroxysmal nocturnal hemoglobinuria Favourite bands: two door cinema club, petit biscuit, kmf, the neighbourhood, mighty oaks, sugarplum fairy + THE KILLERS Favourite solo artists: bosse, clueso, shakira Song stuck in my head: smile like you mean it by the killers Last movie i watched: it’s no movie, but i’m a little obsessed over the o.c. again atm Last tv show i watched: breaktfast tv When did you create your blog: this one in january 2016, but my mainblog sometime in 2012 i think What stuff do you post: ski jumping & biathlon & toni kroos When did you blog reach its peak: uhm, idk, in March maybe. Do you have any other blogs: yes, my mainblog is @thetasteof-spring Do you get asks regularly: hmn, i wouldn’t say so. depends. atm not really because of off season. Why did you choose your url: tbh i really do not know what was wrong with me at that time :D at least it kinda expresses my love for team norge haha. Following: 73 Posts: 3,966  Hogwarts house: pottermore says gryffindor but i’d rather be in ravenclaw :D Pokemon team: idk, shame on me Favourite colours: white, grey, green, blue, rosé Average hours of sleep: if i do not have to get up maybe 8-9, but on weekdays a little less Lucky numbers: 7 and 27 Favourite characters: i really like seth cohen from the o.c., spencer from pll and christina from grey’s anatomy (& probably 100 other persons i just forgot) What are you wearing right now: white t-shirt & grey sweatpants How many blankets do you sleep with: 1 Dream job: i’m still really interested in something to do with sports, like team doctor or something (in the meantime i also had trauma surgery which was probably my fav subject so far and is most similar to sports medicine). but in august i’m also gonna do a clinical traineeship at a hospital in gynecology and midwifery which i’m really looking forward, too. plus: i really loved pediatics lessons. so all in all i’m really far away of making a decision. Dream trip: amsterdam is still my favorite, i would also love to go to the baltic sea or italy again. will see what’s possible during summer holidays. 

i only tag @hulkieswonderland because i miss you here a lot ♥

[azveille]

The top 10 drug launches of 2019

Cancer is probably the most sought-after indication in the biopharma world, but it’s missing from 2019's class of top drug launches. Instead, treatments in immunology and rare genetic diseases have grabbed the limelight.

We considered two EvaluatePharma projections in January and February to rank this year’s top 10 drug launches by 2024 sales. At the top of the list is Alexion’s Soliris follow-up, Ultomiris, which nabbed an FDA nod at the end of 2018, two months ahead of its scheduled decision date.

As part of CEO Ludwig Hantson’s plan for Alexion to pivot away from ultrarare diseases and reach more patients, the biotech has priced Ultomiris at a 10% discount to Soliris and is aiming to convert70% of Soliris patients to the improved therapy. Paroxysmal nocturnal hemoglobinuria (PNH), the current condition Ultomiris is approved in, is a rare disease that involves the immune system.

Notably, two gene therapies are included here: Novartis’ spinal muscular atrophy treatment Zolgensma—which could challenge Biogen’s SMA treatment Spinraza—and Bluebird Bio’s Zynteglo for beta-thalassemia. Gene therapies have attracted much interest and controversy alike. As one-time treatments, they come with big efficacy promises, but pricing of these two drugs has been closely watched, and both companies are offering up novel models such as installments paid over several years.

Novartis boasts three drugs on our list, the most among all companies, putting CEO Vas Narasimhan’s innovative medicine-focused strategy to an early test. Besides Zolgensma, the Swiss drugmaker has brolucizumab, a wet age-related macular degeneration therapy that will go up against Bayer and Regeneron’s Eylea and its Roche-partnered Lucentis. In head-to-head studies, brolucizumab topped Eylea in some secondary endpoints.

Novartis' Mayzent, the first-ever oral drug for secondary progressive multiple sclerosis (SPMS), was approved by the FDA in March. Up to 80% of patients with relapsing remitting MS develop SPMS, but the challenge lies in helping doctors identify those patients. The company is focusing on educating patients and physicians to help raise awareness of this stage of the disease and its symptoms.

In the immunology realm, AbbVie has two potential blockbusters on this list, Skyrizi and upadacitinib. The company is trying to diversify its portfolio as its megablockbuster in the field, Humira, starts to decline amid ex-U.S. biosimilar competition. In a recent note to investors, Credit Suisse analysts predicted that every submarket in the anti-inflammation space, be it arthritis, asthma, inflammatory bowel disease or multiple sclerosis, has room for billions in growth.

Other contenders here include Aimmune Therapeutics’ AR101, which aims to be the first drug that reduces children’s allergic reactions to accidental peanut exposure. It hit a speed bump when its application for FDA approval ran into the government shutdown in December but is now under review—and Aimmune's in talks with the agency about speeding up its approval after that delay.

Two drugs facing new questions as they ramp up round out the list: anemia drug roxadustat, which FibroGen is developing in partnership with AstraZeneca and Astellas, actually has already won its first approval—in China. But a pooled analysis of phase 3 safety on the drug, meant for chronic kidney disease patients, recently sent some confusing signals to investors.

Meanwhile, Johnson & Johnson’s ketamine-like depression nasal spray Spravato is also nothing short of controversial, both around its price tag and safety risks.

As we were publishing this report, Bluebird disclosed a delay in Zynteglo's launch. But we decided to keep it on the list because the biotech is planning to enroll patients within this year and treat the first commercial patients in early 2020.

The 2019 class of top drug launches shows the booming of expensive orphan drugs that are based on novel technologies, as well as the undying enthusiasm about the growing immunology market whose opportunity is evident in the world's best-selling drug Humira. As always, we welcome your thoughts and comments. — Angus Liu (email) (Twitter)

[cryptobully-blog]

Dow pares gains as selling pressure picks up

http://cryptobully.com/dow-pares-gains-as-selling-pressure-picks-up/

Dow pares gains as selling pressure picks up

amzn_assoc_placement = "adunit0"; amzn_assoc_tracking_id = "cryptobully-20"; amzn_assoc_ad_mode = "manual"; amzn_assoc_ad_type = "smart"; amzn_assoc_marketplace = "amazon"; amzn_assoc_region = "US"; amzn_assoc_title = "My Amazon Picks"; amzn_assoc_asins = "B018Y1Q71M,B06XHTKFH3,1973884852,B00PCMSJQS"; amzn_assoc_linkid = "4356926c226bfe54ba2aa66ea72eea8b"; amzn_assoc_search_bar = "true";

The Dow trimmed gains as stocks faced increasing selling pressure Thursday as the halo effect from a series of robust economic data waned while worries over President Trump’s protectionist stance against trading partners continued to cast a shadow.

What are the main benchmarks doing?

The Dow Jones Industrial Average DJIA, +0.47% which has closed lower for three straight sessions, rose 88 points, or 0.4%, to 24,847. It had earlier risen by triple digits to reclaim the 25,000 mark.

The S&P 500 index SPX, -0.08% slid 3 points, or 0.1%, to 2,745 while the Nasdaq Composite COMP, -0.20% fell 22 points, or 0.3%, to 7,474.

What’s driving the markets?

Worries are persisting this week about a potential global trade war after Trump said Wednesday his administration will seek to trim the U.S.’s trade deficit with China by $100 billion. The announcement follows comments the previous day that he wants to impose up to $60 billion in tariffs on Chinese goods.

In a Thursday tweet, the president erroneously said that Canada runs a trade surplus with the U.S., when it is the opposite. The tweet was seemingly in response to a leaked recording from a fundraiser in which Trump boasted to making up facts when speaking with Canada’s Prime Minister Justin Trudeau.

Read more: How investors can protect against a trade war—in one sentence

What data are in focus?

Initial U.S. jobless claims declined by 4,000 to 226,000 in the seven days ended March 10, clinging to a 50-year low.

Both the Philly Fed and Empire State manufacturing indexes were well above zero indicating improving conditions. Both district reported continued high input prices.

Meanwhile, the import price index rose 0.4% in February following an even sharper increase in January, reflecting the higher costs Americans are paying for foreign goods and services.

Check out: MarketWatch’s Economic Calendar

Separately, the National Association of Home Builders’ monthly confidence gauge ticked down one point to a reading of 70 in March. February’s reading was reduced one tick, to 71. Economists surveyed by Econoday had forecast an unchanged reading of 72 in March. That said, any reading over 50 signals improving conditions.

What are strategists saying?

“Economic releases, especially leading indicators still point to an expanding economy, not only in the U.S., but also in Europe and China. But we are closer to the end of the cycle,” said Maris Ogg, president at Tower Bridge Advisors.

“Markets and investors are probably fearing that Trump has done everything he could [in terms of policy] and by now he lost his momentum,” Ogg said.

“We continue to see positive trends in economic fundamentals but valuations that suggest a lot of good news has already been priced in,” wrote Bruce Bittles, chief investment strategist at Baird in a note to investors.

Bittles also predicted stocks to remain rangebound for now. “We have yet to see a sufficient unwinding in investor sentiment or recovery in breadth indicators to argue for a more bullish view. Neither Federal Reserve policy nor seasonal patterns have deteriorated to the point of arguing for a more bearish view.

See: Go big on stocks as Trump has 1 huge reason not to launch a trade war

What stocks are in focus?

Shares in Boeing Co. BA, -0.11% reversed earlier gains to fall 0.7%. The aerospace giant is on track for its biggest weekly decline in over two years, as concerns over the potential negative effects of President Donald Trump’s tariff plan weigh.

Walmart Inc. WMT, -0.17%   shares were off 0.8% following reports that a whistleblower has filed a lawsuit alleging the retailer manipulated its numbers to catch up with Amazon.com Inc. AMZN, -0.52%  

ADT Inc. ADT, -12.44% swung to profit in the fourth quarter as revenue climbed 5.2%. Still, shares sank 10%.

Shares in Solid Biosciences Inc. SLDB, -64.58% plunged after the maker of muscular-dystrophy treatments announced a clinical trial had been put on hold. Its stock was down 63% in early trade.

Shares of biotech Alexion Pharmaceuticals Inc. ALXN, +3.37%  rose 2.6% after the company announced positive results in a trial of a treatment for Paroxysmal nocturnal hemoglobinuria (PNH).

Dollar General Corp.’s stock DG, +4.72% shares rallied 4.3% after the discount retailer reported fourth-quarter same-store sales that beat expectations and gave an upbeat earnings outlook.

How are other assets performing?

European stocks SXXP, +0.52% were mostly higher while Asian markets finished mixed.

Gold futures GCJ8, -0.69% settled lower, while oil futures CLJ8, +0.41% rose and the ICE U.S. Dollar Index DXY, +0.40% edged higher.

March Madness: Live scores and win probabilities of every NCAA Tournament game

—Victor Reklaitis contributed to this article

amzn_assoc_placement = "adunit0"; amzn_assoc_tracking_id = "cryptobully-20"; amzn_assoc_ad_mode = "manual"; amzn_assoc_ad_type = "smart"; amzn_assoc_marketplace = "amazon"; amzn_assoc_region = "US"; amzn_assoc_title = "My Amazon Picks"; amzn_assoc_asins = "B018Y1Q71M,B06XHTKFH3,1973884852,B00PCMSJQS"; amzn_assoc_linkid = "4356926c226bfe54ba2aa66ea72eea8b"; amzn_assoc_search_bar = "true";

Markets

[biology-geology-beaches-india]

The Science Journals of Satyendra Sunkavally, page 23.